CYCN Stock Analysis: Buy, Sell, or Hold?
CYCN - Cyclerion Therapeutics, Inc. Common Stock
$3.89
-0.18 (-4.42%)
âŧ
5d:
+2.64%
30d:
+7.46%
90d:
+23.1%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When CYCN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CYCN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CYCN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CYCN is currently trading at $3.89, which is considered slightly high relative to its 30-day fair value range of $3.48 to $3.90.
Technical Outlook: Technically, CYCN is showing sideways momentum. Immediate support is located at $3.40, while resistance sits at $4.47. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: CYCN scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.00 (+105.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CYCN is showing sideways momentum. Immediate support is located at $3.40, while resistance sits at $4.47. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: CYCN scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.00 (+105.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.48 -
$3.90
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
36.8%
All Signals
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.4%)
- BULLISH: Trading 105.7% below Wall St target ($8.00)
- WARNING: Composite score 37/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.48 -
$3.90
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.40
Resistance Level
$4.47
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.93
Wall Street Target
$8.00
(+105.7%)
Revenue Growth (YoY)
-43.2%
Share & Embed Analysis
Last updated: August 24, 2026 5:52 AM ET
Data refreshes hourly during market hours. Next update: 6:52 AM
Data refreshes hourly during market hours. Next update: 6:52 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CYCN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$560 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 51 HOLD |
